https://www.PR.com/ Latest news releases from PR.com for Alera Bio. Mon, 18 May 2026 03:03:32 -0400 © 2026 PR.com 60 en-us https://www.PR.com/images/logo_white.jpg https://www.PR.com/ 68 69 PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles. https://www.pr.com/press-release/965253 Thu, 09 Apr 2026 03:00:00 -0400 Alera Bio has secured an exclusive global license from BLA Technology, LLC for thyroid hormone-related IP, strengthening its platform for MCT-8 deficiency. The deal expands Alera’s ability to target both neurological and systemic disease drivers, supports its lead program AB-101, reduces development risk, and enables future pipeline growth. [PR.com] https://www.pr.com/press-release/965253 Alera Bio https://www.pr.com/press-release/965111 Wed, 08 Apr 2026 03:00:00 -0400 Alera Bio has appointed Andrew Eisen, MD, PhD, as Chief Scientific Officer, bringing over 20 years of experience in translational medicine and clinical development. With deep expertise in neuroscience, metabolic disease, and myelination, Dr. Eisen will lead the advancement of Alera’s lead program, AB-101, and help drive its mission to develop transformative therapies for patients with severe neurological disorders, [PR.com] https://www.pr.com/press-release/965111 Alera Bio https://www.pr.com/press-release/953303 Tue, 11 Nov 2025 08:00:00 -0500 Alera Bio, a Chicago-based biotech developing therapies for rare neuroendocrine and neurological disorders, announced its inaugural Board of Directors. The board includes leaders in biopharma, clinical practice, and finance, such as Stephen Hill, Mark Prygocki, Renny Griffith, and Cassius Coleman. Their combined expertise will guide Alera Bio as it advances AB-101 for MCT-8 deficiency, an FDA-designated Rare Pediatric [PR.com] https://www.pr.com/press-release/953303 Alera Bio https://www.pr.com/press-release/949513 Fri, 26 Sep 2025 03:00:00 -0400 Alera Bio announced its executive team: Philip Vorhies (CEO), Peter Thomson (CFO), Eric Floyd, PhD (CRO), and Caitlin Murray (GC), supported by expert consultants. Founder Frank Jaeger noted their strength in biotech, finance, regulatory, and legal, positioning Alera to advance AB-101 for MCT-8 deficiency, a rare neurological disorder with FDA Rare Pediatric Disease designation. [PR.com] https://www.pr.com/press-release/949513 Alera Bio https://www.pr.com/press-release/948515 Thu, 18 Sep 2025 13:53:33 -0400 Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in place. [PR.com] https://www.pr.com/press-release/948515 Alera Bio https://www.pr.com/press-release/942290 Thu, 03 Jul 2025 03:00:00 -0400 Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. [PR.com] https://www.pr.com/press-release/942290 Alera Bio